Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Sarcoma 2Salivary Gland Neoplasms 2Neoplasm Metastasis 2Melanoma 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Mouth Neoplasms 1Liver Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Colonic Neoplasms 1Carcinosarcoma 1

Interventions

Specimen Handling 9Paclitaxel 7Magnetic Resonance Spectroscopy 6Carboplatin 6Biopsy 6Nivolumab 5pembrolizumab 3olaparib 3X-Rays 3durvalumab 2ceralasertib 2cediranib 2Taxes 2Immunoglobulin G 2trastuzumab deruxtecan 1sargramostim 1rucaparib 1ribociclib 1rebastinib 1pelcitoclax 1pazopanib 1pamiparib 1liposomal doxorubicin 1cobimetinib 1capivasertib 1cabozantinib 1belinostat 1atezolizumab 1apatinib 1Trabectedin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinosarcoma × trastuzumab deruxtecan × Sarcoma × Clear all
NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡